Synbiotic composition and application thereof

Abstract

The invention relates to a synbiotic composition, which comprises probiotics and dietary fibers, the probiotics are selected from one or more of Bifidobacterium pseudocatenuum HYL95, Faecalibacterium prausnitzii F20 and Eubacterium rectum BPB22, the dietary fibers are selected from dietary fibers, the dietary fibers are selected from dietary fibers, the dietary fibers are selected from dietary fibers, and the probiotics are selected from one or more of Bifidobacterium pseudocatenuum HYL95, Faecalibacterium prausnitzii F20 and Eubacterium rectum BPB22. The dietary fibers are selected from one or more of white hyacinth beans, Chinese wolfberry fruits, red dates, bitter gourds, lotus seeds, buckwheat, Chinese yams, oats, corn stigma and coix seeds. The synbiotics composition disclosed by the invention can be used for remarkably improving the symptoms, such as excessive calorie intake, weight gain, fat accumulation, muscle loss, impaired insulin sensitivity, impaired sugar tolerance, insulin resistance, reduction of the content of short-chain fatty acid in excrement and the like, which are caused by high-fat diet.

Description

Technical Field

[0001] The present invention belongs to the technical fields of compositions, microorganisms, treatment of metabolic diseases and nutrition, and particularly relates to an important specific effect in aspects of intestinal health and treatment of metabolic diseases such as abnormal glycolipid metabolism. Specifically, it relates to a synbiotic composition for improving glycolipid metabolism and its uses. Background Art

[0002] In recent years, great changes have taken place in people's lifestyles, from a traditional plant-based diet to a Western diet mainly based on animal foods. The incidence of chronic metabolic diseases such as obesity and type 2 diabetes has increased significantly. A high-fat diet leads to an imbalance between nutrient intake and consumption, thereby causing disorders in glycolipid metabolism. The main symptoms include fat accumulation, impaired glucose tolerance, insulin resistance, etc., and ultimately lead to obesity, diabetes and a series of complications, imposing a huge medical and economic burden on society.

[0003] Research shows that intestinal microbiota dysbiosis is closely related to chronic metabolic diseases, and dietary nutrition can affect the structure and metabolites of intestinal microbiota. Intestinal microbiota dysbiosis caused by a high-fat diet leads to an increase in opportunistic pathogenic bacteria in the intestine and a decrease in short-chain fatty acid-producing bacteria, thereby affecting the intestinal barrier. Harmful metabolites enter the human circulatory system, leading to systemic chronic inflammation in the human body and further triggering metabolic diseases. High-fiber diet intervention can enrich short-chain fatty acid-producing bacteria, and these bacteria acidify the intestine by producing metabolites such as acetic acid and butyric acid, inhibiting opportunistic pathogenic bacteria, thereby improving type 2 diabetes.

[0004] A synbiotic is a mixture composed of live microorganisms and substrates that can be selectively utilized by microorganisms. It is not just a simple combination of probiotics and prebiotics, but emphasizes the selective support of substrates for live microorganisms. Synbiotics can specifically supplement and support the growth of strains closely related to the improvement of host disease phenotypes, such as the growth of short-chain fatty acid-producing strains in the intestine, thereby more effectively affecting the intestinal environment and repairing intestinal microbiota dysbiosis, and having more clinical application prospects than using probiotics or prebiotics alone. Currently, there are few synbiotics for improving abnormal glycolipid metabolism, and most of the compositions use simple substrates with relatively low molecular weights, such as inulin, oligosaccharides, etc., and their selective support for live microorganisms is limited. Therefore, it is of great significance to develop a synbiotic composition that has a selective support effect on live microorganisms and can improve abnormal glycolipid metabolism. Summary of the Invention

[0005] In view of the problems existing in the prior art, the present invention provides a synbiotic composition, which can provide specific support for the growth of short-chain fatty acid-producing strains and the production of butyric acid by high-molecular-weight fiber substrates, and significantly improve abnormal glycolipid metabolism caused by a high-fat diet.

[0006] To solve the above technical problems, the synbiotic composition provided by the present invention comprises Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ), F20, Eubacterium rectale ( Eubacterium rectale ), BPB22 and dietary fiber.

[0007] In particular, Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ), F20, Eubacterium rectale ( Eubacterium rectale ), BPB22 and high molecular weight soluble dietary fiber YRS of coix seed.

[0008] Among them, the strain of Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), HYL95 is deposited in the China Center for Type Culture Collection (CCTCC), with the deposit number CCTCC NO: M 2025538 and the deposit date of March 20, 2025. The strain of Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ), F20 is deposited in the China Center for Type Culture Collection (CCTCC), with the deposit number CCTCC NO: M 2025537 and the deposit date of March 20, 2025. The strain of Eubacterium rectale ( Eubacterium rectale ), BPB22 is deposited in the China Center for Type Culture Collection (CCTCC), with the deposit number CCTCC NO: M 20232177 and the deposit date of November 10, 2023.

[0009] To solve the above technical problems, the specific technical solutions adopted by the present invention are as follows: In the first aspect of the present invention, a synbiotic composition is provided, comprising probiotics and dietary fiber. The probiotics are selected from one or more of Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ), F20, Eubacterium rectale ( Eubacterium rectale ), BPB22; the dietary fiber is from one or more of white hyacinth bean, wolfberry, red date, balsam pear, lotus seed, buckwheat, Chinese yam, oat, corn silk, coix seed.

[0010] In some specific embodiments, the dietary fiber is soluble dietary fiber.

[0011] In some specific embodiments, the dietary fiber is from one or more of white hyacinth bean, lotus seed, coix seed.

[0012] In some specific embodiments, the probiotics are Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii) F20, Eubacterium rectale ( Eubacterium rectale ) Three probiotics, namely BPB22, and the dietary fiber is soluble dietary fiber of coix seed.

[0013] In some specific embodiments, the ratio of the probiotics to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ) HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectale ( Eubacterium rectale ) BPB22 and the dose ratio range of the high molecular weight soluble dietary fiber of coix seed is (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (50 - 150) g / L.

[0014] In some specific embodiments, the ratio of the probiotics to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ) HYL95, Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ) F20, Eubacterium rectale ( Eubacterium rectale ) BPB22 and the dose ratio of the high molecular weight soluble dietary fiber of coix seed is 5×10 8 CFU / mL: 5×10 8 CFU / mL: 5×10 8 CFU / mL: 100 g / L.

[0015] In the second aspect of the present invention, the use of the synbiotic composition as described above in the preparation of a drug for promoting short-chain fatty acid production in the intestine.

[0016] The use of the synbiotic composition as described above in the preparation of a drug for promoting butyric acid production in the intestine.

[0017] The use of the synbiotic composition as described above in the preparation of a drug for controlling postprandial blood glucose and treating insulin resistance.

[0018] Compared with the prior art, the present invention has the following beneficial effects: 1. The synbiotic composition provided by the present invention can provide high molecular weight dietary fiber substrate-specific support for short-chain fatty acid-producing strains to produce butyric acid.

[0019] 2. The synbiotic composition provided by the present invention can significantly improve symptoms such as excessive calorie intake, weight gain, fat accumulation, muscle loss, impaired insulin sensitivity, impaired glucose tolerance, insulin resistance, and reduced fecal short-chain fatty acid content caused by a high-fat diet.

[0020] The concept of the present invention and the resulting technical effects will be further described below in conjunction with the accompanying drawings to fully understand the purpose, features, and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 In which A is the extraction process of dietary fiber, Figure 1 and B in which are the morphology and nomenclature of 20 kinds of dietary fiber.

[0022] Figure 2 In which A is the pH and acetic acid and butyric acid production of the functional strain mixed fermentation of different fiber substrates, Figure 2 and B in which are the description of the strains used in the experiment and the differential growth of different strains in the culture media of different substrates.

[0023] Figure 3 is the experimental design of the synthetic microbiota composition intervening in high-fat diet mice.

[0024] Figure 4 They are respectively the body weight growth rate (A), food intake (B), energy intake (C), the proportion of 4 kinds of white fat and total white fat in body weight (D), the proportion of vastus lateralis muscle in body weight (E), the average area of epididymal fat cells and the representative HE staining section field of view (F), the non-alcoholic fatty liver disease (NAFLD) activity score of the liver and the representative HE staining section field of view (G) of each group of mice.

[0025] Figure 5 They are respectively the ITT blood glucose curve (A), the area under the ITT blood glucose curve (B), the OGTT blood glucose curve (C), the area under the OGTT blood glucose curve (D), the insulin curve (E), the area under the insulin curve (F), the insulin resistance homeostasis model HOMA-IR index (G), and the product of the area under the OGTT blood glucose curve and the area under the insulin curve from 0 to 60 minutes (H) of each group of mice.

[0026] Figure 6 They are respectively the total short-chain fatty acid content (A), acetic acid content (B), propionic acid content (C), butyric acid content (D), isobutyric acid content (E), valeric acid content (F), and isovaleric acid content (G) of the feces of each group of mice. DETAILED DESCRIPTION OF THE INVENTION

[0027] For a more specific understanding of the technical content, features and effects of the present invention, the technical solutions of the present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments. The described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative work fall within the scope of protection of the present invention.

[0028] Example 1 Extraction of fiber substrates According to the method of GB5009.88-2014 "National Food Safety Standard Determination of Dietary Fiber in Foods", an experimental process for extracting and separating soluble and insoluble dietary fiber components from natural plant raw materials was designed, as shown in A in Figure 1.

[0029] Insoluble dietary fiber and high-molecular-weight soluble dietary fiber of 10 natural raw materials were extracted, including white hyacinth beans, wolfberries, red dates, bitter gourds, lotus seeds, buckwheat, yams, oats, corn silk and coix seeds. The forms and names of 20 different fibers are as Figure 1 shown in B. The raw powder ground from each raw material was dissolved in 0.05M MES-TRIS buffer at a solid-liquid ratio of 1:10, and was successively enzymatically hydrolyzed with thermostable α-amylase at 95°C for 1 h, with alkaline protease at 60°C and pH 7.5 for 30 min, with glucosidase at 60°C and pH 4.5 for 30 min, with trypsin at 37°C and pH 7 for 1 h, and inactivated by boiling at 100°C for 10 min to enzymatically hydrolyze starch, protein, fat, etc. in the raw material powder into various small molecules. The precipitate obtained by centrifuging the enzyme-water extract was collected, washed with ultrapure water, and then freeze-dried and ground to obtain the insoluble dietary fiber part. The supernatant obtained by centrifuging the enzyme-water extract was collected, concentrated, and the soluble dietary fiber therein was precipitated with 4 times the volume of ethanol. The supernatant was discarded, the precipitate was washed with ethanol, and then redissolved with hot water. Sevage reagent was added in a ratio of 1:4 by volume, vortexed and mixed evenly, and then centrifuged to separate. The supernatant was collected, and the lower protein precipitate was discarded. The treatment with Sevage reagent was repeated many times until there was no obvious milky white precipitate. The supernatant was filled into a dialysis bag with a molecular weight cut-off of 7000D for dialysis, and ultrapure water was replaced every 12 hours, repeating 3 times. The dialysis solution retained in the bag was collected, freeze-dried and ground to obtain high-molecular-weight soluble dietary fiber.

[0030] Example 2 In vitro screening of the ability of different fiber substrates to support the production of butyric acid by functional strains The YCFA medium without additional carbon source was used as the negative control (NC), the YCFA medium with an additional final concentration of 0.5% glucose was used as the positive control (GLU), and the YCFA medium with an additional final concentration of 0.5% of 20 different fiber substrates was used as different fermentation media, named asFigure 1 A in Figure 2 Five active functional strains producing short-chain fatty acids isolated from human feces as shown in B of

[0031] Each active strain was inoculated into YCFAG medium at a ratio of 2%, anaerobically statically cultured at 37 °C for 36 h for activation, and then transferred to YCFAG medium at a ratio of 2% and anaerobically statically cultured at 37 °C for 24 h for scale-up culture. After the strain scale-up culture, the cells were collected by centrifugation at 7000 g for 10 minutes, washed with PBS buffer containing 0.1% cysteine, and centrifuged again to remove the residual medium. The cells were resuspended with YCFA medium and diluted to an OD600 of about 1.0. After mixing the 5 functional strains in equal proportions, they were respectively inoculated into the above 22 media at a ratio of 2%, inverted and mixed evenly, and anaerobically cultured at 37 °C for 48 h.

[0032] After 48 h of fermentation, centrifugation was carried out at 10000 g for 10 minutes to collect the supernatant fermentation broth. 20 μL of the supernatant was taken to measure the pH by the phenol red method. 200 μL of the supernatant was taken, 100 μL of 50% sulfuric acid was added to acidify the fermentation broth, and short-chain fatty acids in molecular form were released. Then 400 μL of ether was added, vortexed and mixed evenly, and the short-chain fatty acids were extracted by ether. After standing for 2 min, centrifugation was carried out at 14,000 g at 4 °C for 5 min, and the upper ether phase was taken for on-machine detection.

[0033] After determining the retention times of six short-chain fatty acids (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid), a mixed aqueous solution of six SCFA standard products with concentrations of 0.0025, 0.005, 0.01, 0.02, 0.04 μL / mL was prepared by gradient dilution method, and then acidification, extraction and on-machine determination were carried out on the sample in the same way. An Agilent 6890 gas chromatograph (Agilent Technologies, USA) was used in the experiment, and detection was carried out with a polar HP-FFAP chromatographic column (0.25 mm×0.25 mm×30 m, Agilent Technologies, USA). Helium was used as the carrier gas. The initial temperature of the chromatographic column was 140 °C and lasted for 6 min; it was raised to 250 °C at a rate of 25 °C / min and lasted for 2 min. The inlet temperature was 250 °C and the detector temperature was 280 °C. Finally, the content of short-chain fatty acids in the fermentation broth was calculated according to the standard curve drawn by the standard products. All manual operations were carried out on ice throughout the process.

[0034] The results of the supernatant pH and acetic acid and butyric acid yields are as shown in Figure 2As shown by A in [reference], when white hyacinth bean soluble fiber BBDS, lotus seed soluble fiber LZS, and coix seed soluble fiber YRS are used as substrates, the butyric acid produced by the mixed flora fermenting fiber exceeds that produced by fermenting glucose. This indicates that compared with glucose, these three fiber substrates can better promote the growth and butyric acid production of butyric acid-producing bacteria in the mixed flora, and among them, coix seed soluble fiber YRS has the strongest ability to support the butyric acid production of functional strains.

[0035] Example 3 Evaluation of the specific supporting ability of coix seed soluble fiber on the growth of functional strains Using YCFA medium without additional carbon source as the blank control (NC), YCFA medium with an additional final concentration of 0.5% glucose (GLU) or inulin (INU) as the positive control, and YCFA medium with an additional final concentration of 0.5% coix seed soluble fiber substrate as the fermentation medium. The experiment was carried out using Figure 2 as shown by B in [reference], four opportunistic pathogenic bacteria and five short-chain fatty acid-producing functional strains isolated from human feces were used to perform in vitro fermentation of the coix seed soluble fiber substrate to evaluate the ability of this fiber to specifically support functional strains.

[0036] Each strain was inoculated into the growth medium at a ratio of 2%, anaerobically statically cultured at 37 °C for 36 h for activation, and then transferred to the growth medium at a ratio of 2% and anaerobically statically cultured at 37 °C for 24 h for scale-up culture. After the scale-up culture of the strains, the cells were collected by centrifugation at 7000 g for 10 minutes, washed with PBS buffer containing 0.1% cysteine, and centrifuged again to remove the residual medium. After resuspending the cells with YCFA medium and diluting to an OD600 of about 1.0, each strain was transferred to 4 kinds of media at a ratio of 2%, and the OD600 value was measured after anaerobic culture for 48 h. The results are as shown by B in Figure 2 as shown by B in [reference], each strain can utilize glucose and inulin for growth, and the growth ability in inulin is slightly weaker than that in glucose. However, only 5 active functional strains can utilize coix seed soluble fiber for growth, while 4 opportunistic pathogenic bacteria cannot grow in the coix seed soluble fiber medium, which indicates that coix seed soluble fiber can specifically support the growth of active functional strains.

[0037] Example 4 Improvement of glycolipid metabolism in high-fat diet mice by synbiotic composition In this experiment, 60 8-week-old specific pathogen-free (SPF)-grade male C57BL / 6J mice were used, and the mice were raised in the SPF barrier of the Experimental Animal Center of Shanghai Jiao Tong University. The animal experiment design was as shown by Figure 3As shown. After 2 weeks of adaptation, the mice were randomly divided into 6 groups of 10 mice each. Different interventions were intragastrically administered to the mice according to the groups, and they were allowed to eat and drink freely for 8 weeks. The NC group was fed a control diet and intragastrically administered 200 μL of phosphate buffer solution (PBS) containing 2% skim milk every day. The HFD group was used as the model group and fed a high-fat diet, and intragastrically administered 200 μL of PBS containing 2% skim milk every day. The PGC group was used as the positive control group, fed a high-fat diet, and intragastrically administered 200 μL of PGC synbiotic dissolved in PBS every day, which contained 2% skim milk and 10 8 CFU of the synbiotic PGC per strain. PGC (Pendulum Glucose Control) is a synbiotic capsule containing 5 strains and 1 prebiotic, specifically Clostridium butyricum ( Clostridium beijerinckii ), Clostridium butyricum ( Clostridium butyricum ), Akkermansia muciniphila ( Akkermansia muciniphila ), Eubacterium hallii ( Eubacterium hallii ), Bifidobacterium infantis ( Bifidobacterium infantis ), 100, and chicory inulin. The PGC synbiotic is currently the only synbiotic special medical product proven to be clinically applicable through clinical trials, which can effectively reduce glycated hemoglobin (A1C) and blood glucose peak in type 2 diabetes patients. The F group was fed a high-fat diet and intragastrically administered 200 μL of soluble fiber from coix seed dissolved in PBS every day, which contained 2% skim milk and 20 mg of soluble fiber YRS from coix seed. The S group was fed a high-fat diet and intragastrically administered 200 μL of a strain mixture dissolved in PBS every day, which contained 2% skim milk and 10 8 CFU of Bifidobacterium pseudocatenulatum HYL95, Faecalibacterium prausnitzii F20, and Eubacterium rectale BPB22 each. The FS group was fed a high-fat diet and intragastrically administered 200 μL of a fiber-strain composition dissolved in PBS every day, which contained 2% skim milk, 20 mg of soluble fiber YRS from coix seed, and 10 8 CFU of Bifidobacterium pseudocatenulatum HYL95, Faecalibacterium prausnitzii F20, and Eubacterium rectale BPB22 each. The body weight changes of the mice were recorded during the experiment. An insulin tolerance test (ITT) was conducted in the 7th week of the intervention, and an oral glucose tolerance test (OGTT) was conducted in the 8th week of the intervention. After the OGTT in the 8th week, the mice were sacrificed for sampling. The synbiotic PGC in this example was purchased from Pendulum Therapeutics, Inc., USA.

[0038] The operation methods of the ITT experiment are as follows: Change the bedding of the mice and fast them for 6 h without water deprivation. Weigh the mice before the experiment and intraperitoneally inject insulin into the mice at a dose of 0.75 U / kg body weight. Collect blood from the tail vein of the mice at 0, 15, 30, 45, 60, and 90 minutes, and measure the blood glucose value with a blood glucose meter. The operation methods of the OGTT experiment are as follows: Change the bedding of the mice and fast them for 6 h without water deprivation. Gavage the mice with 25% glucose solution at a dose of 2.0 g / kg body weight. Collect blood from the tail vein of the mice at 0, 15, 30, 60, and 120 minutes, and measure the blood glucose value with a blood glucose meter. Collect tail vein blood at 0, 15, and 60 minutes for insulin measurement. The blood glucose level and insulin level at zero time are fasting blood glucose and fasting insulin. The HOMA-IR index of the insulin resistance homeostasis model = fasting blood glucose × fasting insulin / 22.5.

[0039] Determination of short-chain fatty acids in mouse feces: Place the collected mouse feces samples on dry ice, quickly transfer more than 150 mg of feces into a screw-cap tube and weigh and record. Add 2 volumes of PBS to the screw-cap tube according to w / v = 1:2, and disperse the feces with a toothpick until there are no granular solids. Place the screw-cap tube in the adapter of Tissuelysser II and shake at 20 hz / s for 90 s. Then centrifuge at 4 °C and 16,000 g for 15 minutes, collect the supernatant and transfer it to a new 1.5 mL EP tube, and filter it with a 0.22 µm sterile filter membrane to obtain the feces extract, and measure the short-chain fatty acids as in Example 2.

[0040] Experimental result 1: The synbiotic composition FS can improve the weight gain and increased energy intake of mice caused by a high-fat diet, as shown in Figure 4 A - C therein. The weight growth rate of the mice in the HFD group was significantly higher than that in the NC group, and the food intake was significantly lower than that in the NC group. However, due to the higher energy density of the high-fat diet, the energy intake in the HFD group was significantly higher than that in the NC group. The weight growth rates of the mice in the PGC and FS groups were significantly lower than that in the HFD group, but only the food intake and energy intake in the FS group were significantly lower than those in the HFD group. There were no significant differences in each index between the F and S groups and the HFD group.

[0041] Experimental result 2: The synbiotic composition FS can improve the fat accumulation and muscle loss in mice caused by a high-fat diet, as shown in Figure 4D-G in it. The proportion of total white fat and the average adipocyte area of the four types of white fat in the HFD group of mice were significantly higher than those in the NC group. The non-alcoholic fatty liver disease (NAFLD) activity score of the HFD group of mice was significantly higher than that in the NC group, and there was relatively severe fatty degeneration in the liver, with a large number of lipid vacuoles in hepatocytes. The weight of the vastus lateralis muscle of the HFD group of mice was significantly lower than that in the NC group. The proportion of total white fat and the average adipocyte area of the PGC and FS groups were significantly lower than those in the HFD group. The NAFLD activity score of the FS group was significantly lower than that of the HFD group, and the NAFLD activity score of the PGC group tended to be significantly lower than that of the HFD group. Only the proportion of the vastus lateralis muscle of the FS group of mice tended to be significantly higher than that of the HFD group and was significantly higher than that of the PGC group. There were no significant differences in each index between the F and S groups and the HFD group.

[0042] Experimental result 3: The synbiotic composition FS can improve the impaired insulin sensitivity caused by a high-fat diet, such as Figure 5 A-B in it. The fasting blood glucose, blood glucose at each time point of ITT, and the area under the ITT blood glucose curve of the HFD group were significantly higher than those in the NC group. The blood glucose at multiple time points of ITT and the area under the ITT blood glucose curve of the PGC and FS groups were significantly lower than those in the HFD group. There were no significant differences in each index between the F and S groups and the HFD group.

[0043] Experimental result 4: The synbiotic composition FS can improve the impaired glucose tolerance and insulin resistance in mice caused by a high-fat diet, such as Figure 5 C-H in it. The fasting blood glucose, blood glucose at each time point of OGTT, the area under the OGTT blood glucose curve, fasting insulin, insulin at each time point, the area under the insulin blood glucose curve, the HOMA–IR index representing insulin resistance, and the product of the area under the 0-60-minute OGTT blood glucose curve and the area under the insulin curve of the HFD group were significantly higher than those in the NC group. The area under the OGTT blood glucose curve and the HOMA–IR index of the PGC and FS groups tended to be significantly lower than those in the HFD group. Only the product of the area under the 0-60-minute OGTT blood glucose curve and the area under the insulin curve of the FS group was significantly lower than those of the HFD and PGC groups, and only the area under the insulin blood glucose curve of the FS group tended to be significantly lower than those of the HFD and PGC groups. There were no significant differences in each index between the F and S groups and the HFD group.

[0044] Experimental result 5: The synbiotic composition FS can improve the decrease in the content of fecal short-chain fatty acids in mice caused by a high-fat diet, such as Figure 6Compared with the NC group, the total short-chain fatty acid content in the feces of mice in the HFD group decreased significantly, among which the contents of acetic acid, propionic acid, and valeric acid all decreased significantly, and the contents of butyric acid, isobutyric acid, and isovaleric acid showed a significant downward trend. The interventions in the PGC and FS groups both significantly increased the contents of acetic acid, valeric acid, and total short-chain fatty acids in the feces of mice. Only the intervention in the FS group significantly increased the butyric acid content in the feces of mice. There were no significant differences in each index between the F and S groups and the HFD group.

[0045] The preferred specific embodiments of the present invention have been described in detail above. It should be understood that those of ordinary skill in the art can make many modifications and variations according to the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by those skilled in the art in the technical field based on the concept of the present invention through logical analysis, reasoning, or limited experiments on the basis of the prior art should fall within the protection scope determined by the claims.

Claims

1. A synbiotic composition comprising probiotics and dietary fiber, characterized in that, The probiotics are selected from Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), Faecalibacterium prausnitzii ( Faecalibacterium Prausnitzii ), and Eubacterium rectale ( Eubacterium rectale ); the dietary fiber is from one or more of white hyacinth bean, wolfberry, red date, balsam pear, lotus seed, buckwheat, Chinese yam, oat, corn silk, and coix seed; Among them, the preservation number of the Bifidobacterium pseudocatenulatum is CCTCC NO: M 2025538, the preservation number of the Faecalibacterium prausnitzii is CCTCC NO: M 2025537, and the preservation number of the Eubacterium rectale is CCTCC NO: M 20232177.

2. The synbiotic composition according to claim 1, wherein The dietary fiber is soluble dietary fiber.

3. The synbiotic composition according to claim 2, wherein The dietary fiber comes from white lentils, lotus seeds and coix seeds.

4. The synbiotic composition according to claim 1, wherein The probiotics are Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), Faecalibacterium prausnitzii ( Faecalibacterium Prausnitzii ), and Eubacterium rectale ( Eubacterium rectale ), three kinds of probiotics, and the dietary fiber is soluble dietary fiber of coix seed.

5. The synbiotic composition according to claim 1, characterized in that, The ratio of the probiotic to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ), Eubacterium rectale ( Eubacterium rectale ), BPB22, and the dose ratio range of high molecular weight soluble dietary fiber from coix seed is (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (1×10 7 -1×10 10 ) CFU / mL: (50 - 150) g / L.

6. The synbiotic composition according to claim 5, wherein The ratio of the probiotic to the dietary fiber is Bifidobacterium pseudocatenulatum ( Bifidobacterium pseudocatenulatum ), Faecalibacterium prausnitzii ( Faecalibacterium prausnitzii ), Eubacterium rectale ( Eubacterium rectale ), and the dose ratio of BPB22 and high-molecular-weight soluble dietary fiber from coix seed is 5×10 8 CFU / mL: 5×10 8 CFU / mL: 5×10 8 CFU / mL: 100 g / L.

7. Use of the synbiotic composition according to any one of claims 1 to 6 in the preparation of a drug for promoting the production of short-chain fatty acids in the intestine.

8. Use of the synbiotic composition according to claim 7 in the preparation of a drug for promoting intestinal butyrate production.

9. Use of the synbiotic composition according to any one of claims 1 to 6 in the preparation of a drug for controlling postprandial blood sugar and treating insulin resistance.

Images